SGLT2 inhibitors are primarily used to treat T2DM by inhibiting renal glucose reabsorption, which in turn leads to an increase in urinary glucose excretion and better glycemic control [5]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.